NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.
Oséo, the French Agency for Innovation, is providing funding to Theradiag for work that will be done as part of its participation in CaReNA, a collaboration among drug development firm Splicos, Theradiag, and the French National Center for Research and Science.
Theradiag, a theranostics and in vitro diagnostics company, will develop four new diagnostics kits, including two companion diagnostic tests for therapies from Splicos. One CDx will be for Splicos' therapy for treating HIV/AIDS, the other is for monitoring diabetes and associated metabolic disorders.
These tests will be implemented during the clinical development phases, Theradiag said, allowing physicians to optimize care of their patients.
Theradiag will also develop a test for the early monitoring of HIV infection and disease evolution, and a fourth test will be aimed at assessing patient response and/or resistance to antiretroviral treatments by quantifying predictive miRNAs.
"This new financing will allow us to expand our theranostic range with four new molecular biology/miRNA diagnostic kits, adding on to the existing seven blood-test kits of the Lisa Tracker portfolio," Theradiag's multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies, Theradiag CEO Michel Finance said in a statement.
"With these new kits, we will be able to tap into the broad diagnostic markets of HIV/AIDS and metabolic disorders," Finance added.